ECMO in the newborn.
Since the first use in neonates in 1974, extracorporeal membrane oxygenation (ECMO) has been a life-saving technology for newborns with respiratory and cardiac failure. ECMO has been used to treat a variety of cardio-respiratory problems, including meconium aspiration syndrome (MAS), persistent pulmonary hypertension of the neonate (PPHN), congenital diaphragmatic hernia (CDH), sepsis, and cardiac anomalies. For this group of high-mortality neonates, ECMO has produced a survival of 76% in all newborns treated. This review article will examine the current selection criteria for ECMO, the clinical management of neonates on ECMO and discuss the long-term outcome of neonates treated with ECMO.
Kim
E S
ES
Division of Pediatric Surgery, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Stolar
C J
CJ
D002406:Catheterization, Peripheral; D004569:Electroencephalography; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D018579:Patient Selection; D012127:Respiratory Distress Syndrome, Newborn / Q000628:therapy; D012131:Respiratory Insufficiency / Q000628:therapy; D012140:Respiratory Tract Diseases / Q000628:therapy*; D016896:Treatment Outcome